Date: 2015-07-15
Type of information: Initiation of the trial
phase: 2-3
Announcement: initiation of the trial
Company: AB Science (France)
Product: masitinib in combination with gemcitabine
Action
mechanism: kinase inhibitor/tyrosine kinase inhibitor
Disease: refractory advanced or metastatic epithelial ovarian cancer
Therapeutic area: Cancer - Oncology
Country:
Trial
details:
Latest
news: * On July 15, 2015, AB Science announced the initiation of a seamless adaptive design phase 2/3 study to evaluate the safety and efficacy of masitinib in combination with gemcitabine in patients with refractory advanced or metastatic epithelial ovarian cancer.
This is an international, multicenter, open-label, centrally allocated, active-controlled, phase 2/3 study to evaluate the efficacy and safety of masitinib in combination with gemcitabine as compared with single agent gemcitabine in advanced or metastatic epithelial ovarian cancer patients who are refractory to first line platinum treatment or are in third-line. The study’s primary efficacy measure will be overall survival. The phase 2/3 study has been authorized by competent authorities, and the first patients have been enrolled.
